Payment overview · 2025
General Payments
$502.75
23 reported records · 7 companies
Healthcare provider profile · identity verified
Helene Michelle Davidson, ARNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Primary Care · PORT CHARLOTTE, FL · NPI 1548684889
Verified facts
What the public records show
CMS Open Payments records show Helene Michelle Davidson, ARNP received $502.75 in general payments during 2025 across 23 reported records.
ABBVIE INC. accounted for 36.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $185.60 | 36.9% | 9 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $142.56 | 28.4% | 7 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $65.34 | 13.0% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $37.95 | 7.5% | 2 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $29.74 | 5.9% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $23.65 | 4.7% | 1 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $17.91 | 3.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $502.75 | 23 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $118.64 | 6 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $117.07 | 6 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $112.41 | 6 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $79.97 | 4 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $65.34 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $37.95 | 2 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $29.74 | 1 | 2025 |
Source payment records
|
|||||
| Brinsupri Normalized: brinsupri |
Drug | Insmed, Inc. | $29.74 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $23.65 | 1 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $17.91 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 38 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
38 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 258 | 83 |
| Levothyroxine Sodium | Levothyroxine Sodium | 252 | 66 |
| Atorvastatin Calcium | Atorvastatin Calcium | 233 | 67 |
| Lisinopril | Lisinopril | 230 | 62 |
| Amlodipine Besylate | Amlodipine Besylate | 217 | 65 |
| Metoprolol Succinate | Metoprolol Succinate | 207 | 54 |
| Omeprazole | Omeprazole | 184 | 60 |
| Losartan Potassium | Losartan Potassium | 148 | 43 |
| Metformin Hcl | Metformin Hcl | 140 | 42 |
| Alprazolam | Alprazolam | 136 | 36 |
| Hydrochlorothiazide | Hydrochlorothiazide | 106 | 35 |
| Methylprednisolone | Methylprednisolone | 106 | 87 |
| Trazodone Hcl | Trazodone Hcl | 99 | 28 |
| Sertraline Hcl | Sertraline Hcl | 92 | 28 |
| Doxycycline Hyclate | Doxycycline Hyclate | 85 | 72 |
| Metoprolol Tartrate | Metoprolol Tartrate | 81 | 26 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 74 | 33 |
| Gabapentin | Gabapentin | 73 | 23 |
| Simvastatin | Simvastatin | 71 | 22 |
| Montelukast Sodium | Montelukast Sodium | 64 | 19 |
| Pantoprazole Sodium | Pantoprazole Sodium | 63 | 24 |
| Famotidine | Famotidine | 62 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 62 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 54 | 23 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 54 | 16 |
| Azithromycin | Azithromycin | 53 | 40 |
| Furosemide | Furosemide | 52 | 18 |
| Meloxicam | Meloxicam | 52 | 19 |
| Atenolol | Atenolol | 47 | 12 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 47 | 15 |
| Allopurinol | Allopurinol | 46 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 42 | 11 |
| Alendronate Sodium | Alendronate Sodium | 41 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 41 | 14 |
| Tamsulosin Hcl | Tamsulosin Hcl | 41 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 40 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 40 | 30 |
| Valacyclovir | Valacyclovir Hcl | 40 | 14 |
| Eliquis | Apixaban | 39 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 39 | 11 |
| Tramadol Hcl | Tramadol Hcl | 39 | 16 |
| Ozempic | Semaglutide | 38 | 12 |
| Clopidogrel | Clopidogrel Bisulfate | 37 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 37 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 35 | suppressed |
| Methocarbamol | Methocarbamol | 35 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 35 | suppressed |
| Carvedilol | Carvedilol | 33 | suppressed |
| Potassium Chloride | Potassium Chloride | 33 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 32 | suppressed |
| Nifedipine Er | Nifedipine | 30 | suppressed |
| Celecoxib | Celecoxib | 28 | suppressed |
| Ibuprofen | Ibuprofen | 25 | suppressed |
| Diazepam | Diazepam | 24 | suppressed |
| Estradiol | Estradiol | 24 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 23 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 23 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 23 | suppressed |
| Synthroid | Levothyroxine Sodium | 22 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 22 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 21 | suppressed |
| Chlorthalidone | Chlorthalidone | 20 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 20 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 19 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 19 | suppressed |
| Lorazepam | Lorazepam | 19 | suppressed |
| Lovastatin | Lovastatin | 19 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 19 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 19 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 18 | suppressed |
| Linzess | Linaclotide | 18 | suppressed |
| Baclofen | Baclofen | 17 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 17 | suppressed |
| Spironolactone | Spironolactone | 17 | suppressed |
| Clonazepam | Clonazepam | 16 | suppressed |
| Levofloxacin | Levofloxacin | 16 | 14 |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Glimepiride | Glimepiride | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Bupropion Xl | Bupropion Hcl | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Pregabalin | Pregabalin | 14 | suppressed |
| Prempro | Estrogen,con/M-Progest Acet | 14 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 13 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 13 | suppressed |
| Ezetimibe | Ezetimibe | 13 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 13 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Latanoprost | Latanoprost | 12 | suppressed |
| Mirtazapine | Mirtazapine | 12 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 12 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Xarelto | Rivaroxaban | 12 | suppressed |
| Cefdinir | Cefdinir | 11 | 11 |
| Fenofibrate | Fenofibrate,micronized | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $502.75 · 23 records | ABBVIE INC. | Arikayce, Brinsupri, Cologuard Collection Kit, FARXIGA, JARDIANCE, Ozempic, QULIPTA, Rybelsus, UBRELVY, ZENPEP | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error